Urodynamic Profiles of Various Detrusor Overactivity Types in BPO

Overview

This study examines the impact of detrusor overactivity (DO) on urodynamic parameters in patients with benign prostatic obstruction (BPO). Significant differences in maximum cystometric capacity and bladder compliance were observed between patients with and without DO, highlighting the clinical relevance of DO subtypes.

Background

Benign prostatic hyperplasia (BPH) is prevalent among older men and often leads to lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO). Detrusor overactivity (DO) is a common complication in BPH patients, affecting their quality of life and complicating treatment strategies. Understanding the urodynamic profiles associated with different DO types can inform clinical management and improve patient outcomes.

Data Highlights

Key Findings

• Patients with BPO and DO showed significantly lower maximum cystometric capacity (MCC) compared to those without DO.
• Bladder compliance (BC) was also significantly lower in the BPO with DO group.
• Terminal detrusor overactivity (TDO) was associated with more pronounced storage-phase changes than phasic detrusor overactivity (PDO).
• Age was identified as an independent risk factor for DO, while first desire to void (FD) served as a protective factor.
• A significant negative correlation was found between maximum contraction amplitude of DO and BC in the TDO cohort.

Clinical Implications

Clinicians should consider the presence of detrusor overactivity when evaluating patients with benign prostatic obstruction, as it significantly affects urodynamic parameters. Understanding the subtype of DO can guide treatment decisions and improve patient counseling regarding expected outcomes.

Conclusion

This study underscores the importance of assessing detrusor overactivity in patients with benign prostatic obstruction, as it is linked to significant alterations in urodynamic profiles. Further research is warranted to explore these findings in larger, age-adjusted cohorts.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Frontiers in Medicine, 2026 -- Non-invasive prediction of detrusor underactivity in benign prostatic hyperplasia: an interpretable machine learning framework to optimize surgical selection
3. World Journal of Urology, 2026 -- Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH
4. EAU Guidelines on Non-Neurogenic Male LUTS, 2025
5. American Urological Association, 2026 -- Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia guideline
6. Fundamental Mechanisms of Urgency: The Impact and Advantages of Pharmacological Treatment
7. https://d56bochluxqnz.cloudfront.net/documents/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2025.pdf
8. American Urological Association Releases the Management of
9. The Clinical Significance of the Subtypes of Detrusor Overactivity: A Systematic Review - PMC
10. Incidence of Overactive Bladder Symptoms and Dysuria Following Transurethral Interventions for Benign Prostatic Enlargement: A Systematic Review and Meta-Analysis of Comparative and Randomized Studies - PubMed
11. Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial - PubMed
12. Efficacy and Safety of Mirabegron and Tamsulosin Combination Therapy Compared to Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Multicenter, Randomized, Double-Blind, Phase III Clinical Trial - PMC